<table>
<thead>
<tr>
<th>Product Name</th>
<th>Product Developer</th>
<th>Stage of Development</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Intravaginal Rings (IVRs)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Copper Intravaginal Ring (Cu-IVR)</td>
<td>University of California, Davis</td>
<td>Early Preclinical</td>
<td>HSV-2, Zika virus, Pregnancy</td>
</tr>
<tr>
<td>Dapivirine + Pritelivir + Levonorgestrel 3D Printed IVR</td>
<td>University of North Carolina, Chapel Hill</td>
<td>Early Preclinical</td>
<td>HIV, HSV-2, Pregnancy</td>
</tr>
<tr>
<td>Islatravir (Efda) + Etonogestrel/Ethinyl Estradiol 3D Printed IVR</td>
<td>University of North Carolina, Chapel Hill</td>
<td>Early Preclinical</td>
<td>HIV, Pregnancy</td>
</tr>
<tr>
<td>90-day Pod-type Etonogestrel/Ethinyl Estradiol/QGriffithsin (EEQ) IVR</td>
<td>Population Council</td>
<td>Early Preclinical</td>
<td>HIV, Pregnancy</td>
</tr>
<tr>
<td>Novel mAb contraceptive + Tenofovir Disoproxil Fumarate (TDF) IVR</td>
<td>Oak Crest Institute of Science, Univ. of North Carolina, Chapel Hill</td>
<td>Early Preclinical</td>
<td>HIV, Pregnancy</td>
</tr>
<tr>
<td>Dolutegravir (DTG) + Rilpivirine (RPV) + Acyclovir + Ethinyl Estradiol + Etonogestrel IVR</td>
<td>Auritec Pharmaceuticals</td>
<td>Advanced Preclinical</td>
<td>HIV, HSV-2, Pregnancy</td>
</tr>
<tr>
<td>Human Contraceptive Antibody (HCA) + VRC01 + N6 IVR</td>
<td>MUCCOMMUNE LLC</td>
<td>Advanced Preclinical</td>
<td>HIV, Pregnancy</td>
</tr>
<tr>
<td>mAb 2C7 + TDF IVR</td>
<td>University of Massachusetts</td>
<td>Advanced Preclinical</td>
<td>Gonorrhea, HIV</td>
</tr>
<tr>
<td>Dapivirine + Levonorgestrel IVR</td>
<td>IPM</td>
<td>Phase 1 Clinical Trial</td>
<td>HIV, Pregnancy</td>
</tr>
<tr>
<td>Tenofovir IVR</td>
<td>CONRAD</td>
<td>Phase 2 Clinical Trial</td>
<td>HIV, HSV-2</td>
</tr>
<tr>
<td>Tenofovir + Levonorgestrel IVR</td>
<td>CONRAD</td>
<td>Phase 2 Clinical Trial</td>
<td>HIV, HSV-2, Pregnancy</td>
</tr>
<tr>
<td><strong>Gels (Vaginal &amp; Rectal)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Griffithsin Gel</td>
<td>University of Louisville</td>
<td>Early Preclinical</td>
<td>Hepatitis C, HIV, HSV-2</td>
</tr>
<tr>
<td>VivaGel® Vaginal Gel</td>
<td>StarPharma Ltd.</td>
<td>Advanced Preclinical</td>
<td>BV, HIV, HPV, HSV-2</td>
</tr>
<tr>
<td>Yaso-GEL</td>
<td>Yaso Therapeutics</td>
<td>Advanced Preclinical</td>
<td>Chlamydia, Gonorrhea, HIV, HPV, HSV-2, Pregnancy</td>
</tr>
<tr>
<td>MIV-150 and zinc acetate in carrageenan gel (PC-1005)</td>
<td>Population Council</td>
<td>Phase 2 Clinical Trial</td>
<td>HIV, HPV, HSV-2</td>
</tr>
<tr>
<td>EVO100 Gel</td>
<td>Evofem Biosciences, Inc.</td>
<td>Phase 3 Clinical Trial</td>
<td>Chlamydia, Gonorrhea, Pregnancy</td>
</tr>
<tr>
<td><strong>Fast-dissolving Inserts (FDIs) (Vaginal)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amphora fast-dissolving vaginal insert (FDI)</td>
<td>Evofem Biosciences, Inc., Population Council</td>
<td>Early Preclinical</td>
<td>BV, Chlamydia, Gonorrhea, Pregnancy</td>
</tr>
<tr>
<td>Amphora/QGriffithsin (QGRFT) fast-dissolving vaginal insert (FDI)</td>
<td>Evofem Biosciences, Inc., Population Council</td>
<td>Early Preclinical</td>
<td>BV, Chlamydia, Gonorrhea, HIV, Pregnancy</td>
</tr>
<tr>
<td>Tenofovir Alafenamide (TAF) / Elvitegravir Topical Insert</td>
<td>CONRAD</td>
<td>Phase 1 Clinical Trial</td>
<td>HIV, HSV-2</td>
</tr>
</tbody>
</table>

For more information visit [www.MPTs101.org](http://www.MPTs101.org)
### The MPT Pipeline by Delivery Method

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Product Developer</th>
<th>Stage of Development</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Films (Vaginal)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EFdA-P + Progestin Intravaginal Film</td>
<td>Magee-Women’s Research Inst. &amp; Fndn.</td>
<td>Early Preclinical</td>
<td>HIV, Pregnancy</td>
</tr>
<tr>
<td>MB66 Film</td>
<td>Mapp Biopharmaceutical, Inc.</td>
<td>Phase 1 Clinical Trial</td>
<td>HIV, HSV-2</td>
</tr>
<tr>
<td><strong>Implants</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subcutaneous Contraceptive + HIV Implant</td>
<td>RTI</td>
<td>Early Preclinical</td>
<td>HIV, Pregnancy</td>
</tr>
<tr>
<td>Engineered for Long-Acting Delivery (SCHIELD)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(SCHIELD) device</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Microarray Patches</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MPT Microarray Patch</td>
<td>PATH</td>
<td>Early Preclinical</td>
<td>HIV, Pregnancy</td>
</tr>
<tr>
<td><strong>Oral Tablets</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dual Prevention Pill (DPP) Regimen</td>
<td>Population Council</td>
<td>Phase 4 Clinical Trial</td>
<td>HIV, Pregnancy</td>
</tr>
</tbody>
</table>

To learn more about the MPT pipeline, check out the interactive online MPT Product Development Database at [www.MPTS101.org](http://www.MPTS101.org)